Skip to Content

Alecensa Approval History

Alecensa (alectinib) is an oral anaplastic lymphoma kinase (ALK) inhibitor for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Development History and FDA Approval Process for Alecensa

DateArticle
Dec 11, 2015Approval FDA Approves Alecensa (alectinib) for ALK-Positive Non-Small Cell Lung Cancer
Sep  8, 2015FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
May 13, 2015Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People with Specific Type of Lung Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide